Centessa Pharmaceuticals plc
CNTA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CNTA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CNTA
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company focused on discovering and developing transformational medicines, with a pipeline centered on orexin receptor agonists (OX2R) and its LockBody technology platform, and a cash runway into mid-2028.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 5 pipeline candidates · 5 clinical trials for Centessa Pharmaceuticals plc.
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company focused on discovering and developing transformational medicines, with a pipeline centered on orexin receptor agonists (OX2R) and its LockBody technology platform, and a cash runway into mid-2028.
- Cash, cash equivalents and investments of $533.7 million as of March 31, 2026, expected to fund operations into mid-2028 [sec_mda · as of 2026-05-05].
- No product revenue generated to date; company has incurred recurring losses and negative cash flows from operations since inception [sec_mda · as of 2026-05-05].
- Pipeline includes clinical-stage candidates ORX750, ORX142, and ORX489, targeting orexin receptor 2 (OX2R) for sleep/wake disorders [sec · filed 2025-06-17].
- LockBody technology platform is a key enabling technology for the company's drug discovery and development efforts [sec · filed 2025-06-17].
- Phase 3 topline data for a lead candidate is anticipated by December 31, 2027 [upcoming catalysts].
What works
- Strong cash position of $533.7 million as of March 31, 2026, providing a runway into mid-2028 to advance pipeline programs [sec_mda · as of 2026-05-05].
- Proprietary LockBody technology platform may enable differentiated product candidates with improved safety or efficacy profiles [sec · filed 2025-06-17].
- Multiple clinical-stage candidates (ORX750, ORX142, ORX489) targeting a validated biology (OX2R) for disorders with high unmet need [sec · filed 2025-06-17].
What to weigh
- No approved products or product revenue; company is entirely dependent on successful development and commercialization of current or future candidates [sec_mda · as of 2026-05-05].
- History of recurring losses and negative cash flows from operations; substantial additional funding will likely be required to complete development and commercialization [sec_mda · as of 2025-11-05].
- Clinical development risks include challenges in patient recruitment, safety/tolerability, and efficacy; any delays or failures could materially impact the company [sec · filed 2025-06-17].
- If unable to raise capital on attractive terms, the company may be forced to delay, reduce, or eliminate research or development programs [sec_mda · as of 2025-11-05].
From the filings
Quoted directly from source documents.
Cash runway into mid-2028
“we expect cash, cash equivalents and investments as of March 31, 2026 of $533.7 million to fund our operations into mid-2028”
SEC MD&A · May 5, 2026
Dependence on successful development and commercialization
“The ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of current or future product candidates.”
SEC MD&A · March 31, 2026
Risk of needing additional funding
“If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate research and development programs or future commercialization efforts.”
SEC MD&A · November 5, 2025
Catalyst timeline
- 2027-12-31 · Phase3_Topline — Phase 3 Topline: A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerab — Topline data from a Phase 3 study of a lead candidate is expected by the end of 2027, which will be a key efficacy and safety readout.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has no product revenue and depends entirely on successful development and regulatory approval of candidates [sec_mda · as of 2026-05-05].
- Clinical development risks — Risks include patient recruitment, safety/tolerability, and efficacy; delays or failures could materially harm the company [sec · filed 2025-06-17].
- Need for substantial additional capital — Recurring losses and negative cash flows; if funding is not available, programs may be delayed or eliminated [sec_mda · as of 2025-11-05].
- Dependence on single platform — Pipeline heavily relies on LockBody technology and OX2R agonists; failure of platform could impact multiple programs [sec · filed 2025-06-17].
What to watch
- Enrollment and data readouts from ongoing clinical trials of ORX750, ORX142, and ORX489 [sec · filed 2025-06-17].
- Any updates on cash runway or additional financing needs, given the expectation of increasing expenses [sec_mda · as of 2025-11-05].
- Regulatory milestones and potential approval decisions for lead candidates [upcoming catalysts].
- Progress of the LockBody technology platform in enabling new product candidates [sec · filed 2025-06-17].
Sources: SEC filings · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Centessa Pharmaceuticals plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Centessa Pharmaceuticals plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
12.0 months
D/E 0.32 · 0% dilution
Lead: Phase 2/Phase 3
5 candidates
No upcoming catalysts tracked
0 buys · 16 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
156
Total value held
$4.21B
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 10,517,806 | $417.8M |
| adage capital partners gp, l.l.c. | 8,925,010 | $354.5M |
| pentwater capital management lp | 8,170,000 | $324.5M |
| janus henderson group plc | 6,985,954 | $277.5M |
| fmr llc | 6,852,047 | $272.2M |
| farallon capital management llc | 4,809,000 | $191.0M |
| tcg crossover management, llc | 4,286,480 | $170.3M |
| morgan stanley | 4,268,353 | $169.5M |
| paradigm biocapital advisors lp | 3,574,048 | $142.0M |
| deep track capital, lp | 3,158,041 | $125.4M |
Showing top 10 of 156 institutional holders of Centessa Pharmaceuticals plc. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 2.6%
- Days to cover
- 0.7
- Shares short
- 3,468,688
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CNTA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Centessa Pharmaceuticals plc?
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company focused on discovering and developing transformational medicines, with a pipeline centered on orexin receptor agonists (OX2R) and its LockBody technology platform, and a cash runway into mid-2028.
What is Centessa Pharmaceuticals plc's lead drug candidate?
Centessa Pharmaceuticals plc's most advanced tracked candidate is cleminorexton (Phase 2/Phase 3) for Narcolepsy Type 1.
Who is the CEO of Centessa Pharmaceuticals plc?
Dr. Mario Alberto Accardi Ph.D. is the chief executive officer of Centessa Pharmaceuticals plc (CNTA).
Where is Centessa Pharmaceuticals plc headquartered?
Centessa Pharmaceuticals plc (CNTA) is headquartered in Altrincham, United Kingdom.
What therapeutic areas does Centessa Pharmaceuticals plc focus on?
Centessa Pharmaceuticals plc develops therapies across Oncology, Rare Disease, Neurology, Hematology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.